HBK Sorce Advisory LLC Sells 8,105 Shares of Alphatec Holdings, Inc. $ATEC

HBK Sorce Advisory LLC reduced its position in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 28.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 20,430 shares of the medical technology company’s stock after selling 8,105 shares during the quarter. HBK Sorce Advisory LLC’s holdings in Alphatec were worth $227,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. Larson Financial Group LLC bought a new stake in Alphatec during the first quarter valued at $54,000. Nisa Investment Advisors LLC boosted its position in shares of Alphatec by 22.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock valued at $63,000 after purchasing an additional 1,045 shares in the last quarter. FORA Capital LLC bought a new stake in shares of Alphatec during the 1st quarter valued at about $102,000. PKS Advisory Services LLC bought a new stake in shares of Alphatec during the 1st quarter valued at about $111,000. Finally, R Squared Ltd bought a new stake in shares of Alphatec during the 2nd quarter valued at about $114,000. 66.35% of the stock is owned by institutional investors.

Alphatec Price Performance

Shares of ATEC opened at $18.99 on Friday. Alphatec Holdings, Inc. has a 12-month low of $6.97 and a 12-month high of $20.15. The business’s fifty day moving average is $15.28 and its 200 day moving average is $13.27. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22. The stock has a market cap of $2.81 billion, a P/E ratio of -16.81 and a beta of 1.05.

Alphatec (NASDAQ:ATEC) last released its quarterly earnings data on Thursday, October 30th. The medical technology company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.09. The business had revenue of $196.50 million during the quarter, compared to the consensus estimate of $182.78 million. During the same period last year, the business posted ($0.28) earnings per share. The firm’s quarterly revenue was up 30.4% on a year-over-year basis. Alphatec has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Patrick Miles sold 300,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $15.73, for a total value of $4,719,000.00. Following the transaction, the chief executive officer owned 5,564,078 shares in the company, valued at $87,522,946.94. This trade represents a 5.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Tyson Eliot Marshall sold 18,092 shares of the firm’s stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $14.91, for a total value of $269,751.72. Following the completion of the transaction, the general counsel owned 438,331 shares in the company, valued at $6,535,515.21. This represents a 3.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 901,616 shares of company stock worth $14,290,496 in the last 90 days. Company insiders own 20.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ATEC. Stifel Nicolaus began coverage on Alphatec in a report on Tuesday, October 28th. They set a “buy” rating and a $20.00 price target on the stock. JPMorgan Chase & Co. began coverage on shares of Alphatec in a research note on Friday, October 24th. They set an “overweight” rating and a $19.00 target price on the stock. Wells Fargo & Company increased their target price on shares of Alphatec from $14.00 to $16.00 and gave the stock an “overweight” rating in a research note on Thursday, October 16th. Lake Street Capital set a $25.00 target price on shares of Alphatec and gave the stock a “buy” rating in a research note on Friday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Alphatec in a research note on Tuesday, October 14th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $22.00.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.